RXi Obtains License to RNAi Delivery Technology From UMass Medical School

Luke Timmerman10/14/08

RXi Pharmaceuticals, a Worcester, MA-based developer of drugs based on RNA interference technology, said today it has obtained an exclusive worldwide license to certain technology for oral delivery of RNAi drugs. The technology was developed by Michael Czech and Gary Ostroff at the University of Massachusetts Medical School. Financial terms were not disclosed.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.